Mannkind (MNKD) Stock
Inhalable insulin developer for the diabetes market. Here's the price, business snapshot, and what's worth knowing about Mannkind in September 2026.
MannKind Corporation (MNKD) is a small-cap biopharmaceutical company best known for Afrezza, an inhalable insulin product for people with diabetes. Investors should know MannKind’s value proposition centres on its inhalation delivery technology and commercial efforts to grow Afrezza sales, pursue new indications and explore licensing or partnership opportunities. Financial performance can be uneven: revenue depends heavily on product uptake, distribution arrangements and any new regulatory or reimbursement developments. The company has R&D and regulatory risk typical of biotech firms, plus market competition from other diabetes therapies. MannKind does not currently offer a dividend, and its shares can be volatile. This summary is for general educational purposes only and is not personalised investment advice; always consider your risk tolerance and do further research or consult a professional before investing.
Why You’ll Want to Watch This Stock
Afrezza revenue potential
Afrezza is the main commercial asset and could drive growth if uptake or label expansion improves, although sales trends have been uneven and outcomes are uncertain.
Inhaled delivery focus
Proprietary inhalation technology differentiates the company and may enable licensing opportunities, but technical, regulatory and commercial hurdles remain.
Partnerships & markets
Collaborations and market access are important for scaling reach; changes in reimbursement or competitive diabetes therapies can materially affect prospects.
